Medistem and Cytori Therapeutics Enter Into Licensing Agreement

Medistem and Cytori Therapeutics Enter Into Licensing Agreement 
SAN DIEGO, CA -- (Marketwired) -- 07/18/13 --  Medistem, Inc.
(PINKSHEETS: MEDS), today announced that it entered into an agreement
granting Cytori Therapeutics, Inc. (NASDAQ: CYTX) a license and the
exclusive rights to use Medistem's U.S. Patent No. 8,241,621, "Stem
Cell Mediated Treg Activation" in the United States. 
The licensed patent pertains to Cytori's Adipose-Derived Regenerative
Cell (ADRC) based platform for the treatment of autoimmune diseases. 
"We are delighted to have formalized a licensing agreement with an
adult stem cell leader like Cytori and look forward to working with
them in the future," said Alan J. Lewis, Ph.D., CEO of Medistem. 
"We are pleased to have licensed this patent from Medistem because it
strengthens our patent portfolio in the area of immune disease," said
Marc H. Hedrick, President of Cytori Therapeutics.  
About Medistem, Inc. 
Medistem, Inc., is focused on the development of the Endometrial
Regenerative Cell (ERC), a universal donor adult stem cell product.
ERCs possess specialized abilities to stimulate new blood vessel
growth and can differentiate into lung, liver, heart, brain, bone,
cartilage, fat and pancreatic tissue. These unique properties have
applications for treatment of critical limb ischemia (CLI),
congestive heart failure (CHF), neurodegenerative diseases, liver
failure, kidney failure, and diabetes. ERCs have been cleared by the
FDA to begin studies in the United States. In January 2012, we
announced the initiation of our RECOVER-ERC (Non-Revascularizable
IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous
DElivery of Cell TheRapy) Phase II clinical trial. This trial is
being conducted at the Bakulev Scientific Center for Cardiovascular
Surgery, Moscow, Russia. The trial is a 60 patient double blind
placebo controlled study evaluating safety and efficacy of ERCs in
end stage CHF patients.  
Certain statements herein may be forward-looking and involve risks
and uncertainties. Such forward-looking statements involve
assumptions, known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements of
Medistem, Inc. These can be identified by the use of forward-looking
words, such as "believes", "expects", "may", "intends",
"anticipates", "plans", "estimates", or any other analogous or
similar expressions intended to identify forward-looking statements.
These forward-looking statements and estimates as to future
performance, estimates, and other statements contained herein
regarding matters that are not historical facts, are only predictions
and actual events or results may differ materially. We cannot assure
or guarantee that any future results described in this presentation
will be achieved, and actual results could differ materially as a
result of a variety of factors, including the risks associated with
the effect of changing economic conditions and other risk factors
detailed in the Company's Securities and Exchange Commission filings.
The Company undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise. 
Contact: 
John P. Salvador
626.644.6092
john.salvador@medisteminc.com 
 
 
Press spacebar to pause and continue. Press esc to stop.